Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
April 25, 2024 08:00 ET
|
Compass Therapeutics
CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study...
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
April 12, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
March 21, 2024 09:00 ET
|
Compass Therapeutics
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
February 29, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Provides Corporate Update
January 05, 2024 08:00 ET
|
Compass Therapeutics
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer...
Compass Therapeutics to Participate in Upcoming Investor Events
November 07, 2023 08:00 ET
|
Compass Therapeutics
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Biliary Tract Cancer Market to Register Stunning Growth by 2032, Examines DelveInsight | Key Companies to Watch Out - Merck, AstraZeneca, Taiho Oncology, Basilea, Eisai, Zymeworks, BeiGene, Xencor, BMS, Leap
August 28, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Biliary Tract Cancer Market to Register Stunning Growth by 2032, Examines DelveInsight | Key Companies to Watch Out - Merck, AstraZeneca, Taiho...
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
June 22, 2023 16:05 ET
|
Compass Therapeutics
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
May 04, 2023 08:30 ET
|
Compass Therapeutics
Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half...
Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 19, 2023 08:30 ET
|
Compass Therapeutics
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...